A Phase 1 interventional study of Finerenone (BAY94-8862): 20 mg intact tablet and Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet in Pharmacokinetics, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-24.
Sponsored by Bayer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a novel liquid formulation for the treatment of children in comparison to the adult tablet formulation.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 20 mg intact finerenone tablet fasting
Drug: Finerenone (BAY94-8862): 20 mg intact tablet
Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
Drug: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
Single oral dose of 20 mg finerenone suspension fasting
Drug: Finerenone (BAY94-8862): 20 mg suspension
Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
Drug: Finerenone (BAY94-8862): 20 mg suspension
20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
Drug page: Finerenone
20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
Finerenone area under the plasma concentration vs. time curve (AUC)
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours
Finerenone maximum plasma concentration (Cmax)
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours
Appearance of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Taste of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Texture of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Smell of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Overall impression of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Number of patients with adverse events as a measure of safety and tolerability
Time frame: Up to 4 weeks
Ran from Nov 2016 to primary completion in Jan 2017, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone